# US 2015/0147278 A1 · Antibody against transporter and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147278 A1
- Document ID: US20150147278A1
- Status: Published application
- Kind: A1
- Application number: 14/561,944
- Filed: 2014-12-05
- Published: 2015-05-28
- Earliest claimed: 2012-06-08
- Assignees: Kinki University; Link Genomics, Inc.
- Applicants: Kinki University; Link Genomics, Inc.
- Inventors: Takashi Masuko; Shinichiro Niwa; Hidemi Hayashi; Dai Ogura; Takayuki Shindou
- Web page: https://patentgrep.com/patent/US20150147278A1

## CPC

- C07K 16/30: from tumour cells
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61P 35/00: Antineoplastic agents
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/3015: {Breast}
- C07K 16/3023: {Lung}
- C07K 16/303: {Liver or Pancreas}
- C07K 16/3038: {Kidney, bladder}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/3053: {Skin, nerves, brain}
- C07K 16/3061: {Blood cells}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/624: Disulfide-stabilized antibody (dsFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/77: Internalization into the cell
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.

## Claims

### Claim 1

An antibody or an antigen-binding fragment thereof, each specifically binding to the extracellular region of the LAT1/CD98 complex in LAT1/CD98-expressing cells, which is:
(1) an antibody or an antigen-binding fragment thereof, which comprises, as light chain complementarity determining region 1 (CDRL1), light chain complementarity determining region 2 (CDRL2) and light chain complementarity determining region 3 (CDRL3), the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively, and
which comprises, as heavy chain complementarity determining region 1 (CDRH1), heavy chain complementarity determining region 2 (CDRH2) and heavy chain complementarity determining region 3 (CDRH3), the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, respectively;
(2) an antibody or an antigen-binding fragment thereof, which comprises, as CDRL1, CDRL2 and CDRL3, the amino acid sequences of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, respectively, and
which comprises, as CDRH1, CDRH2 and CDRH3, the amino acid sequences of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18, respectively;
(3) an antibody or an antigen-binding fragment thereof, which comprises, as CDRL1, CDRL2 and CDRL3, the amino acid sequences of SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21, respectively, and
which comprises, as CDRH1, CDRH2 and CDRH3, the amino acid sequences of SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24, respectively; or
(4) an antibody or an antigen-binding fragment thereof, which comprises, as CDRL1, CDRL2 and CDRL3, the amino acid sequences of SEQ ID NO: 25, SEQ ID NO: 26 and SEQ ID NO: 27, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO: 25, SEQ ID NO: 26 and SEQ ID NO: 27, respectively, and
which comprises, as CDRH1, CDRH2 and CDRH3, the amino acid sequences of SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30, respectively.

### Claim 2

An antibody or an antigen-binding fragment thereof, each specifically binding to the extracellular region of the LAT1/CD98 complex in LAT1/CD98-expressing cells, which comprises:
(1) light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence X1ASQX2VGNNVA (SEQ ID NO: 1);
(2) light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence YASX3RX4T (SEQ ID NO: 2);
(3) light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QRX5YKSPYT (SEQ ID NO: 3);
(4) heavy chain complementarity determining region 1 (CDR 1) comprising the amino acid sequence GFSLPTSSVS (SEQ ID NO: 4);
(5) heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence VIWSNGNTDYSSX6X7KS (SEQ ID NO: 5); and
(6) heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence NFRNX8PGVMDA (SEQ ID NO: 6)
(provided that X1 to X8 are each any naturally occurring amino acid residue).

### Claim 3 (depends on 2)

The antibody or antigen-binding fragment thereof according to claim 2, wherein (SEQ ID NOS 39-43)
X1 is R or K,
X2 is N or T,
X3 is S or N,
X4 is H or N,
X5 is V or I,
X6 is A or R,
X7 is I or F, and
X8 is D or N.

### Claim 4 (depends on 2)

The antibody or antigen-binding fragment thereof according to claim 2, wherein
(SEQ ID NOS 7-9 and 11-12)
(1) X1 is R, X2 is N, X3 is N, X4 is N, X5 is I,
X6 is A, X7 is I, and X8 is D,
(SEQ ID NOS 13-15 and 17-18)
(2) X1 is K, X2 is N, X3 is S, X4 is H, X5 is V,
X6 is R, X7 is F, and X8 is D,
(SEQ ID NOS 19-21 and 23-24)
(3) X1 is K, X2 is T, X3 is S, X4 is H, X5 is V,
X6 is R, X7 is F, and X8 is D,
or
(SEQ ID NOS 25-27 and 29-30)
(4) X1 is K, X2 is N, X3 is S, X4 IS H, X5 is V,
X6 is R, X7 is I, and X8 is N.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, which contains:
(1) a light chain variable region (VL) comprising an amino acid sequence sharing an identity of 90% or more with the amino acid sequence of SEQ ID NO: 31, and
a heavy chain variable region (VH) comprising an amino acid sequence sharing an identity of 90% or more with the amino acid sequence of SEQ ID NO: 32;
(2) a light chain variable region (VL) comprising an amino acid sequence sharing an identity of 90% or more with the amino acid sequence of SEQ ID NO: 33, and
a heavy chain variable region (VH) comprising an amino acid sequence sharing an identity of 90% or more with the amino acid sequence of SEQ ID NO: 34;
(3) a light chain variable region (VL) comprising an amino acid sequence sharing an identity of 90% or more with the amino acid sequence of SEQ ID NO: 35, and
a heavy chain variable region (VH) comprising an amino acid sequence sharing an identity of 90% or more with the amino acid sequence of SEQ ID NO: 36; or
(4) a light chain variable region (VL) comprising an amino acid sequence sharing an identity of 90% or more with the amino acid sequence of SEQ ID NO: 37, and
a heavy chain variable region (VH) comprising an amino acid sequence sharing an identity of 90% or more with the amino acid sequence of SEQ ID NO: 38.

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, which contains:
(1) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 31, and
a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 32;
(2) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 33, and
a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 34;
(3) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 35, and
a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 36; or
(4) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 37, and
a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 38.

### Claim 7 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, which has cytotoxic activity and/or internalization activity on LAT1/CD98-expressing cells.

### Claim 8 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, whose subclass is IgG.

### Claim 9 (depends on 8)

The antibody or antigen-binding fragment thereof according to claim 8, wherein the IgG is IgG2a or IgG1.

### Claim 10 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, wherein the antigen-binding fragment is any of Fab, Fab′, F(ab′)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies and multimers thereof, or a bispecific antibody fragment.

### Claim 11 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, which is a monoclonal antibody.

### Claim 12 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, which is a rat, mouse, primate or human antibody.

### Claim 13 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, which is a chimeric antibody or a humanized antibody.

### Claim 14 (depends on 1)

An immunoconjugate, which comprises the antibody or antigen-binding fragment thereof according to claim 1 and at least one cytotoxic drug, antitumor agent or radioisotope.

### Claim 15 (depends on 1)

An isolated nucleic acid molecule, which encodes the antibody or antigen-binding fragment thereof according to claim 1.

### Claim 16 (depends on 15)

An expression vector, which comprises the nucleic acid molecule according to claim 15.

### Claim 17 (depends on 1)

A hybridoma cell or a transgenic cell, each producing the antibody according to claim 1, which comprises the nucleic acid molecule which encodes the antibody or antigen-binging fragment thereof according to claim 1, or is transformed with the nucleic acid molecule.

### Claim 18 (depends on 17)

A method for preparation of a monoclonal antibody specifically binding to the extracellular region of the LAT1/CD98 complex, which comprises culturing the cell according to claim 17 and collecting an antibody specifically binding to the LAT1/CD98 complex from the resulting cultured product.

### Claim 19 (depends on 17)

A method for preparation of a monoclonal antibody specifically binding to the extracellular region of LAT1/CD98, which comprises isolating a gene encoding an anti-LAT1/CD98 monoclonal antibody from the cell according to claim 17, constructing an expression vector comprising the gene, introducing the expression vector into a host to cause expression of the monoclonal antibody, and collecting the monoclonal antibody specifically binding to the extracellular region of LAT1/CD98 from the resulting host, the culture supernatant of the host or the secretory product of the host.

### Claim 20 (depends on 19)

The method for preparation according to claim 19, wherein the host is E. coli, a yeast cell, an insect cell, a mammalian cell, a plant cell or a mammal.

### Claim 21 (depends on 1)

A composition containing the antibody or antigen-binding fragment thereof or immunoconjugate thereof according to claim 1, which is used for induction of apoptosis by being applied to LAT1/CD98-expressing cells.

### Claim 22 (depends on 1)

A pharmaceutical preparation for prevention or treatment of tumor, which contains the antibody or antigen-binding fragment thereof or immunoconjugate thereof according to claim 1.

### Claim 23 (depends on 1)

A composition containing the antibody or antigen-binding fragment thereof or immunoconjugate thereof according to claim 1, which is used for detection of LAT1/CD98-expressing cells.

### Claim 24 (depends on 23)

A method for detection of tumor, which comprises reacting the composition according to claim 23 with a sample taken from a living organism and detecting the reacted signals.

### Claim 25 (depends on 23)

A method for in vitro immunological detection of tumor, which comprises the step of contacting the composition according to claim 23 with cancer cells.

### Claim 26 (depends on 23)

A method for in vivo imaging of tumor, which comprises the steps of administering the composition according to claim 23 to a subject and obtaining a detection image by near-infrared optical imaging, PET, MRI or ultrasonic imaging.

### Claim 27 (depends on 1)

A pharmaceutical preparation for diagnosis of tumor, which contains the antibody or antigen-binding fragment thereof or immunoconjugate thereof according to claim 1.

### Claim 28 (depends on 22)

The pharmaceutical preparation according to claim 22, wherein the tumor is at least one selected from the group consisting of colorectal cancer, colon and rectal cancer, lung cancer, breast cancer, brain tumor, melanoma, renal cell carcinoma, bladder cancer, leukemia, lymphoma, T cell lymphoma, multiple myeloma, gastric cancer, pancreatic cancer, uterine cervical cancer, endometrial cancer, ovarian cancer, esophageal cancer, liver cancer, head and neck squamous cell carcinoma, skin cancer, urinary tract cancer, prostate cancer, choriocarcinoma, pharyngeal cancer, laryngeal cancer, tongue cancer, oral cancer, gallbladder cancer, thyroid cancer, mesothelioma, pleural tumor, arrhenoblastoma, endometrial hyperplasia, endometriosis, embryoma, fibrosarcoma, Kaposi's sarcoma, hemangioma, cavernous hemangioma, hemangioblastoma, retinoblastoma, astrocytoma, neurofibroma, oligodendroglioma, medulloblastoma, neuroblastoma, neuroglioma, rhabdomyosarcoma, glioblastoma, osteogenic sarcoma, leiomyosarcoma, thyroid sarcoma, and Wilms tumor.

### Claim 29

A complementarity determining region (CDR), which is selected from the group consisting of (1) to (6) shown below:
(1) light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO: 7, 13, 19 or 25;
(2) light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO: 8, 14, 20 or 26;
(3) light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO: 9, 15, 21 or 27;
(4) heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO: 10, 16, 22 or 28;
(5) heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO: 11, 17, 23 or 29; and
(6) heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO: 12, 18, 24 or 30.

### Claim 30 (depends on 5)

A chimeric antigen receptor (CAR) comprising the heavy chain variable region (VH) and the light chain variable region (VL) as defined in (1), (2), (3) or (4) of claim 5.

### Claim 31 (depends on 30)

A genetically modified T cell having the CAR according to claim 30 being expressed on its surface (CAR-T cell).

### Claim 32 (depends on 31)

A method for treatment of cancer comprising the steps of contacting the genetically engineered T cell (CAR-T cell) according to claim 31 with a cancer cell of a patient, and inducing apoptosis of the cancer cell.

### Claim 33 (depends on 31)

A pharmaceutical composition for treatment of cancer comprising the genetically engineered T cell (CAR-T cell) according to claim 31 and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 27)

The pharmaceutical preparation according to claim 27, wherein the tumor is at least one selected from the group consisting of colorectal cancer, colon and rectal cancer, lung cancer, breast cancer, brain tumor, melanoma, renal cell carcinoma, bladder cancer, leukemia, lymphoma, T cell lymphoma, multiple myeloma, gastric cancer, pancreatic cancer, uterine cervical cancer, endometrial cancer, ovarian cancer, esophageal cancer, liver cancer, head and neck squamous cell carcinoma, skin cancer, urinary tract cancer, prostate cancer, choriocarcinoma, pharyngeal cancer, laryngeal cancer, tongue cancer, oral cancer, gallbladder cancer, thyroid cancer, mesothelioma, pleural tumor, arrhenoblastoma, endometrial hyperplasia, endometriosis, embryoma, fibrosarcoma, Kaposi's sarcoma, hemangioma, cavernous hemangioma, hemangioblastoma, retinoblastoma, astrocytoma, neurofibroma, oligodendroglioma, medulloblastoma, neuroblastoma, neuroglioma, rhabdomyosarcoma, glioblastoma, osteogenic sarcoma, leiomyosarcoma, thyroid sarcoma, and Wilms tumor.

### Claim 35 (depends on 6)

A chimeric antigen receptor (CAR) comprising the heavy chain variable region (VH) and the light chain variable region (VL) as defined in (1), (2), (3) or (4) of claim 6.
